Literature DB >> 34629281

Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy.

Ahmet Murat Aydin1, Richard R Reich2, Biwei Cao2, Salim K Cheriyan3, Ali Hajiran3, Logan Zemp3, Alice Yu3, Michael A Poch3, Wade J Sexton3, Roger Li3, Scott M Gilbert4.   

Abstract

BACKGROUND: To assess predictors, indicators and medical necessity of readmissions after neoadjuvant chemotherapy and radical cystectomy in order to identify opportunities for reducing readmission rates.
METHODS: Records for patients treated with cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy between 2007 and 2017 were reviewed for 90-day complications and readmission. Readmissions were classified as necessary vs. discretionary based on independent clinician review. The association between postoperative complications and necessary or discretionary readmission were examined with adjusted regression models.
RESULTS: Among a total of 250 patients, 76 patients (30.4%) were readmitted within 90 days of surgery (19 discretionary and 57 necessary). Age, insurance coverage, and comorbidity were similar between readmitted and non-readmitted patients. Readmission was more likely after neobladder than ileal conduit (39% vs. 23%, P = 0.02). Major (grade ≥ 3) complications within 90-day of surgery including index admission and post-discharge period were significantly more common among re-admitted patients compared to patients who were not readmitted (40% in necessary, 21% in discretionary, 3% in none, P < 0.001). Median length of stay on readmission was twice as long in necessary cases compared to discretionary cases (5 vs. 2.5 days, P < 0.001). Gastrointestinal and infectious complications were associated with discretionary readmission in adjusted analyses, while infectious, renal/genitourinary and thromboembolic complications were associated with necessary readmission.
CONCLUSIONS: Twenty-five percent of readmissions were categorized as discretionary and were driven primarily by low-grade gastrointestinal complications, marginal oral intake and failure to thrive, suggesting that better coordinated post-discharge supportive care could help avoid a substantial proportion of readmissions.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complications; Cystectomy; Muscle-invasive bladder cancer; Neoadjuvant chemotherapy; Patient readmission; Urinary bladder cancer

Mesh:

Year:  2021        PMID: 34629281      PMCID: PMC8960322          DOI: 10.1016/j.urolonc.2021.09.001

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  31 in total

1.  Few modifiable factors predict readmission following radical cystectomy.

Authors:  Brian J Minnillo; Matthew J Maurice; Nicholas Schiltz; Aiswarya C Pillai; Siran M Koroukian; Firouz Daneshgari; Sim P Kim; Robert Abouassaly
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

Review 2.  Prevention and management of complications following radical cystectomy for bladder cancer.

Authors:  Nathan Lawrentschuk; Renzo Colombo; Oliver W Hakenberg; Seth P Lerner; Wiking Månsson; Arthur Sagalowsky; Manfred P Wirth
Journal:  Eur Urol       Date:  2010-02-26       Impact factor: 20.096

3.  Surgical approach as a determinant factor of clinical outcome following radical cystectomy: Does Enhanced Recovery After Surgery (ERAS) level the playing field?

Authors:  Jian Chen; Hooman Djaladat; Anne K Schuckman; Monish Aron; Mihir Desai; Inderbir S Gill; Thomas G Clifford; Saum Ghodoussipour; Gus Miranda; Jie Cai; Siamak Daneshmand
Journal:  Urol Oncol       Date:  2019-07-05       Impact factor: 3.498

4.  Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy.

Authors:  Carlotta Palumbo; Sophie Knipper; Angela Pecoraro; Giuseppe Rosiello; Stefano Luzzago; Marina Deuker; Zhe Tian; Shahrokh F Shariat; Claudio Simeone; Alberto Briganti; Fred Saad; Alfredo Berruti; Alessandro Antonelli; Pierre I Karakiewicz
Journal:  Surg Oncol       Date:  2019-10-25       Impact factor: 3.279

5.  Development of a comorbidity index using physician claims data.

Authors:  C N Klabunde; A L Potosky; J M Legler; J L Warren
Journal:  J Clin Epidemiol       Date:  2000-12       Impact factor: 6.437

6.  Exploring the burden of inpatient readmissions after major cancer surgery.

Authors:  Karyn B Stitzenberg; YunKyung Chang; Angela B Smith; Matthew E Nielsen
Journal:  J Clin Oncol       Date:  2014-12-29       Impact factor: 44.544

7.  Improved Outcomes of Enhanced Recovery After Surgery (ERAS) Protocol for Radical Cystectomy with Addition of a Multidisciplinary Care Process in a US Comprehensive Cancer Care Center.

Authors:  Sephalie Y Patel; Rosemarie E Garcia Getting; Brandon Alford; Karim Hussein; Braydon J Schaible; David Boulware; Jae K Lee; Scott M Gilbert; Julio M Powsang; Wade J Sexton; Philippe E Spiess; Michael A Poch
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

8.  Incidence and Predictors of 30-Day Readmission in Patients Treated With Radical Cystectomy: A Single Center European Experience.

Authors:  Marco Moschini; Giorgio Gandaglia; Paolo Dell'Oglio; Nicola Fossati; Vito Cucchiara; Giusy Burgio; Agostino Mattei; Rocco Damiano; Shahrokh F Shariat; Andrea Salonia; Francesco Montorsi; Alberto Briganti; Renzo Colombo; Andrea Gallina
Journal:  Clin Genitourin Cancer       Date:  2015-12-23       Impact factor: 2.872

9.  Hospitalisation and readmission costs after radical cystectomy in a nationally representative sample: does urinary reconstruction matter?

Authors:  Gregory A Joice; Meera R Chappidi; Hiten D Patel; Max Kates; Nikolai A Sopko; C J Stimson; Phillip M Pierorazio; Trinity J Bivalacqua
Journal:  BJU Int       Date:  2018-07-26       Impact factor: 5.588

10.  Early recovery after surgery for radical cystectomy: comprehensive assessment and meta-analysis of existing protocols.

Authors:  F Wessels; M Lenhart; K F Kowalewski; V Braun; T Terboven; F Roghmann; M S Michel; P Honeck; M C Kriegmair
Journal:  World J Urol       Date:  2020-03-02       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.